Seventeen research firms currently cover Jazz Pharmaceuticals. Of these, thirteen analysts have issued buy recommendations, three have assigned hold ratings and one has recommended selling the stock. The average one-year price objective among brokers updating their coverage in the past year stands at $205.67. Notable adjustments include JPMorgan reducing its target from $204.00 to $199.00 while maintaining an overweight view, Truist raising its outlook from $220.00 to $230.00 with a buy rating, and Robert W. Baird lifting its objective from $160.00 to $209.00 alongside an outperform designation.

Director Heather Ann McSharry disposed of 3,415 shares on November 20th, representing a 14.31% reduction in her holding. Chief Accounting Officer Patricia Carr sold 4,660 shares on December 5th, trimming her ownership by 39.92%. Collectively, insiders offloaded 123,791 shares during the last quarter, equivalent to approximately $21.99 million in total value. Following these transactions, company officers and directors retain 4.30% of total outstanding shares.

Institutional investors account for 89.14% of Jazz’s outstanding shares. In the third quarter, EverSource Wealth Advisors increased its stake by 9.0% to 983 shares, Tectonic Advisors added 1.5% to reach 5,626 shares and Fairbanks Capital Management grew its position by 0.4% to 25,023 shares. In the second quarter, Teacher Retirement System of Texas boosted its holding by 0.6% to 15,560 shares, while Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its position by 8.7% to 1,250 shares.

Jazz Pharmaceuticals maintains a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The company’s market capitalization stands at approximately $9.95 billion. Profitability measures include a negative price-to-earnings ratio of 26.97 and a P/E/G ratio of 0.75, while the stock’s beta is 0.27, indicating lower volatility relative to the broader market.